Incyte (INCY) – Analysts’ Recent Ratings Updates

Incyte (NASDAQ: INCY) has recently received a number of price target changes and ratings updates:

• 7/23/2026 – Incyte had its price target raised by Morgan Stanley from $103.00 to $104.00. They now have an “equal weight” rating on the stock.
• 7/23/2026 – Incyte had its price target raised by JPMorgan Chase & Co. from $105.00 to $110.00. They now have a “neutral” rating on the stock.
• 7/21/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $140.00 price target on the stock.
• 7/15/2026 – Incyte had its “market perform” rating reaffirmed by Citigroup Inc..
• 7/14/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright.
• 7/14/2026 – Incyte had its price target raised by Barclays PLC from $117.00 to $134.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Incyte had its price target raised by BMO Capital Markets from $94.00 to $112.00. They now have a “market perform” rating on the stock.
• 7/7/2026 – Incyte had its price target raised by Royal Bank Of Canada from $95.00 to $99.00. They now have a “sector perform” rating on the stock.
• 6/29/2026 – Incyte had its “buy (b-)” rating reaffirmed by Weiss Ratings.
• 6/26/2026 – Incyte had its price target raised by UBS Group AG from $103.00 to $113.00. They now have a “neutral” rating on the stock.
• 6/24/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $140.00 price target on the stock.
• 6/22/2026 – Incyte was upgraded by BMO Capital Markets from “underperform” to “market perform”. They now have a $94.00 price target on the stock, up from $75.00.
• 6/22/2026 – Incyte had its price target raised by Truist Financial Corporation from $103.00 to $105.00. They now have a “hold” rating on the stock.
• 6/15/2026 – Incyte had its “underperform” rating reaffirmed by BMO Capital Markets.
• 6/9/2026 – Incyte was given a new $123.00 price target by Stifel Nicolaus.
• 6/9/2026 – Incyte had its “hold” rating reaffirmed by TD Cowen.
• 6/9/2026 – Incyte had its price target raised by HC Wainwright from $135.00 to $140.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Incyte had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $107.00 price target on the stock.
• 6/2/2026 – Incyte had its “market perform” rating reaffirmed by Citigroup Inc..

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.